Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Pretubulysin: a new option for the treatment of metastatic cancer.

Braig S, Wiedmann RM, Liebl J, Singer M, Kubisch R, Schreiner L, Abhari BA, Wagner E, Kazmaier U, Fulda S, Vollmar AM.

Cell Death Dis. 2014 Jan 16;5:e1001. doi: 10.1038/cddis.2013.510.

2.

Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition.

von Schwarzenberg K, Wiedmann RM, Oak P, Schulz S, Zischka H, Wanner G, Efferth T, Trauner D, Vollmar AM.

J Biol Chem. 2013 Jan 11;288(2):1385-96. doi: 10.1074/jbc.M112.412007. Epub 2012 Nov 20.

3.

The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1.

Wiedmann RM, von Schwarzenberg K, Palamidessi A, Schreiner L, Kubisch R, Liebl J, Schempp C, Trauner D, Vereb G, Zahler S, Wagner E, Müller R, Scita G, Vollmar AM.

Cancer Res. 2012 Nov 15;72(22):5976-87. doi: 10.1158/0008-5472.CAN-12-1772. Epub 2012 Sep 17.

4.

Cotargeting stress-activated Hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer.

Kumano M, Furukawa J, Shiota M, Zardan A, Zhang F, Beraldi E, Wiedmann RM, Fazli L, Zoubeidi A, Gleave ME.

Mol Cancer Ther. 2012 Aug;11(8):1661-71. doi: 10.1158/1535-7163.MCT-12-0072. Epub 2012 Jun 6.

5.

Pretubulysin: from hypothetical biosynthetic intermediate to potential lead in tumor therapy.

Herrmann J, Elnakady YA, Wiedmann RM, Ullrich A, Rohde M, Kazmaier U, Vollmar AM, Müller R.

PLoS One. 2012;7(5):e37416. doi: 10.1371/journal.pone.0037416. Epub 2012 May 17.

6.

Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD.

Zoubeidi A, Zardan A, Wiedmann RM, Locke J, Beraldi E, Fazli L, Gleave ME.

Cancer Res. 2010 Mar 15;70(6):2307-17. doi: 10.1158/0008-5472.CAN-09-3252. Epub 2010 Mar 2. Erratum in: Cancer Res. 2011 Jul 15;71(14):5054.

7.

The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis.

Rothmeier AS, Schneiders UM, Wiedmann RM, Ischenko I, Bruns CJ, Rudy A, Zahler S, Vollmar AM.

Int J Cancer. 2010 Sep 1;127(5):1096-105. doi: 10.1002/ijc.25241.

Supplemental Content

Loading ...
Support Center